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Abstract
Background: Although medical oncologists can have an important role in controlling the cost of cancer treatment, 
there is little information about their attitudes toward the cost of cancer treatment and the impact of cost on their 
treatment recommendations, especially in low- and middle-income countries (LMICs). In this study, we assessed the 
attitude of Iranian medical oncologists toward some economic aspects of new cancer drugs. 
Methods: We translated a questionnaire that was used in similar studies in the United States and Canada into Persian 
and modified it according to the local setting in Iran. The face and content validity of the questionnaire were assessed by 
oncologists before being used in the survey. We distributed the questionnaire and collected the data from 80 oncologists 
who participated in the 13th Annual Congress of the Iranian Society of Medical Oncology and Hematology (ISMOH). 
Results: Fifty-two oncologists participated in our study (a response rate of 65%). The majority of oncologists stated 
that drug costs and patient out-of-pocket (OOP) costs influence their treatment recommendations (92% and 94%, 
respectively). Most oncologists (70%) felt that they are ready enough to use cost-effectiveness information in their 
treatment decisions, and 74% believed that patients should only have access to cancer treatments that are cost-effective. 
Most oncologists agree that the government should have control over drug prices, and more use of cost‐effectiveness 
data is required for decision-making about cancer drug coverage. Ninety-one percent of oncologists said that they 
always or frequently discuss cancer treatment costs with their patients. Oncologists believed that academic groups 
(research centers and scientific societies) (81%) and the Ministry of Health (MoH) (43%) are the most eligible groups 
for determining whether a drug provides good value. 
Conclusion: Iranian medical oncologists are ready to participate in the health technology assessment and priority-
setting process. This situation creates a unique opportunity for the government to rely on scientific societies and find an 
appropriate solution for the improvement of patients’ access to high-quality care. 
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Implications for policy makers
• The high prices of new cancer drugs affect oncologists’ treatment recommendations and their patients’ access to effective treatments.
• Iranian medical oncologists agree that government should have control over drug prices.
• It seems that Iranian medical oncologists are ready to participate in the health technology assessment and priority-setting process.
Implications for public
Some of the new cancer drugs impose high financial costs on cancer patients, their families and society. Patient-physician communication about 
the clinical benefits and costs of chemotherapy drugs seems to be necessary during the decision-making process for treatment planning in cancer 
patients. Patients and their caregivers should take this opportunity and involve themselves in the discussion with their doctors. Clinicians should apply 
appropriate tools and methods to communicate with their patients and help them make appropriate decisions.
Key Messages 
Background
Recently, the high price of new cancer drugs has created much 
debate in the medical literature and mass media.1-3 Despite a 
moderate impact of some new cancer drugs on patient survival 
and quality of life, their prices are very high, so most likely 
some of them are not cost-effective, especially in low- and 
middle-income countries (LMICs) whose cost-effectiveness 
threshold is low.4 According to the World Bank classification, 
LMICs are those who had a gross national income per capita 
of less than $12 746 in 2013.5 The World Health Organization 
(WHO) has recommended a cost-effectiveness threshold of 
less than 3 times the GDP per capita.6 However, Kantarjian 
et al7 showed in their article that most new cancer drugs cost 
more than $70 000 per patient annually in the United States. 
They stated that the correlation between the price of a new 
cancer drug and its effectiveness is low. Of 12 anticancer 
drugs approved by the U.S. Food and Drug Administration 
(FDA) in 2012, only 3 led to improvement in survival, of 
which 2 improved survival by less than 2 months. Although 
the price of drugs in the United States are somewhat higher 
than in other countries,2 it seems that, consistent with the 
WHO recommendation, most new cancer drugs may not be 
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cost-effective in LMICs. 
Although new cancer drugs improve patients’ outcome, they 
impose high financial costs on patients, their families and 
health systems.4,8,9 The price of new cancer drugs is too high, 
so even the national health systems in high-income countries 
cannot publicly fund them.10 Thus patients have to pay drug 
costs out-of-pocket (OOP). 
The public sector has the main role in the provision of 
healthcare in Iran. The private sector mostly provides 
secondary and tertiary care in urban areas. There are 3 
major types of healthcare financing in Iran: general revenue 
financing, social healthcare insurance, and household OOP 
payments. The private healthcare insurance market is small 
in the country. However, before implementation of the 
Health Evolution Plan, around 10% of the population had 
no healthcare insurance coverage and more than 50% of 
healthcare costs were paid by patients.11 For cancer patients, 
the majority of OOP payments were for drugs costs.12 The 
Health Evolution Plan, which started in May 2014, has 3 
main objectives: to provide financial protection against 
health expenditures, to enhance equity in access to healthcare 
services, and to improve the quality of healthcare services.13 In 
the first phase of the plan, the government insured more than 
7 million people who were under no insurance previously, and 
covered up to 90% of hospitalization costs for insured patients 
at public hospitals. Preliminary evaluations have shown that 
the plan reduced OOP payments by 10%.13 However, as most 
of the new and expensive cancer drugs are out of insurance 
coverage in Iran, patients must pay the drug costs OOP. OOP 
payments, therefore, drag patients into poverty or limit their 
access to effective treatments.4,14-16 
The process of decision-making in relation to drug 
reimbursement in Iran is quite similar to other countries. 
In the process, several criteria, such as clinical effectiveness, 
safety, cost-effectiveness and budget impact, are used. 
However, the drug reimbursement system in Iran has 
several drawbacks, including high OOP payments, due to 
a lengthy decision-making process, a lack of transparency 
and conflicting stakeholder interests.17 Because of these 
shortcomings, the drug reimbursement system in Iran cannot 
assess and appraise new expensive cancer drugs quickly 
and accurately. For example, in 2010, several years after 
Trastuzumab had entered the market in Iran, health policy-
makers found that this drug imposed a significant financial 
burden on the Iranian patients and government, so the 
Ministry of Health (MoH) decided to implement a national 
program for the regula tion of Trastuzumab prescriptions 
in Iran.10 Another example was Nilotinib (Tasigna); it took 
more than one year to develop guidance for this drug by 
specialists and the guideline development office of the MoH. 
In the guidance, Nilotinib was recommended as a second- 
or third-line treatment for chronic myeloid leukemia. But 
before implementation of the guidance, the Food and Drug 
Organization, which determines the drugs that are eligible 
for coverage by governmental subsidies, added Nilotinib to 
the subsidized drug list. As a result, the drug’s sales increased 
about six times during the following year in Iran (from $1 to 
$6 million).18
On the other hand, the prevalence of cancer is increasing in 
the world, especially in LMICs, including Iran.19 Thus, new 
and expensive cancer treatments will impose a significant 
economic burden on LMICs in the future. Since most of these 
countries are facing a severe shortage of resources, they must 
look for ways to control cancer treatment costs. For example, 
in the last decade the cost of cancer drugs nearly doubled in 
Iran and reached about US$350 million in 2014. More than 
70% of the cost of cancer drugs is related to drugs imported 
from other countries.18
Medical oncologists can have an important role in controlling 
the cost of cancer treatments.20 They are the main decision-
makers in the treatment process and decide what medications 
a patient should use.21 Although oncologists want their patients 
to receive the treatment that provides the greatest benefit, 
however, they must also consider the costs of treatment, 
because high-cost treatment may impose a financial burden 
on patients and society and reduce their welfare.4
Previous studies in the United States, Canada, Australia, 
and Israel examined the attitude of medical oncologists 
toward the cost of new cancer drugs.3,22-26 The results of a 
survey of 1355 United States and 238 Canadian medical 
oncologists conducted by Berry et al showed that patient 
OOP costs influence the treatment recommendations of most 
oncologists in both countries (84% the United States, 80% 
Canadian). Moreover, the majority of oncologists believed that 
governments should control the price of cancer drugs (57% 
the United States, 68% Canadian).22 In another survey of 167 
US oncologists, 86% of respondents reported that they were 
aware of their patients’ financial well-being. Furthermore, 
80% of respondents strongly agreed or agreed that “it is 
important to be explicit with patients about the financial 
consequences of treatment options.”24 Likewise the results of a 
survey of 184 Australian oncologists showed that the price of 
cancer drugs influences their treatment recommendations.25 
Also, in a survey on 52 Israeli oncologists, 77% of them stated 
that inclusion of a cancer drug in the National List of Health 
Services influenced their treatment recommendations, and 
92% believed that it affected their patients’ access to treatment. 
In addition, 73% believed that cost-effectiveness analysis 
should be used in coverage decisions for cancer drugs.26
Although medical oncologists can have an important 
role in controlling the cost of cancer treatment, there is 
little information about their attitudes toward the cost of 
cancer treatment and the impact of cost on their treatment 
recommendations, especially in LMICs. In this study, we 
assessed the attitudes of Iranian medical oncologists toward 
some economic aspects of cancer treatment, including the 
costs and cost-effectiveness of cancer drugs and related health 
policies.
Methods
This study was conducted with the coordination and support 
of the Iranian Society of Medical Oncology and Hematology 
(ISMOH). Almost all medical oncologists and hematologists 
in Iran are members of ISMOH and the society has about 
200 members across the country. We used the convenience 
sampling method and conducted our survey during the 13th 
Annual Congress of ISMOH, where most Iranian oncologists 
were available and had time to complete the survey questions, 
assuming that they will be representative of the total Iranian 
oncologists. 
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We used a questionnaire that was developed previously for 
the same purpose in the United States and Canada.3,22 We 
translated the questionnaire into Persian and modified 
it for the local setting. The face and content validity of the 
questionnaire were assessed by a few oncologists before 
using the survey (the survey instrument can be found in 
Appendix 1). The questionnaire consisted of 14 statements 
and we asked oncologists to indicate their level of agreement 
with each statement on a 5-point Likert scale: strongly agree, 
somewhat agree, neither agree nor disagree, somewhat 
disagree, and strongly disagree. 
We distributed the questionnaire among 80 oncologists who 
were participating in the 13th Annual Congress of ISMOH. 
The Congress team announced the survey in the main hall 
and asked the participants to complete the survey during the 
first day. The completed questionnaires were collected during 
the breaks and at the end of the day.
We used IBM SPSS 20 software (SPSS Inc., Chicago, IL) and 
performed descriptive data analysis. 
Results
The response rate was 65% and 52 out of 80 participants 
completed the survey. Table 1 shows the characteristics of the 
respondents. The mean age of the study participants was 46 
(range: 36–68) and 88% were male. Most of the oncologists 
(50%) practiced in both the public and private sectors. About 
80% of the oncologists visited more than 50 patients per week.
Table 2 shows oncologists’ attitudes toward the cost of cancer 
drugs and cost-effectiveness. The majority of oncologists 
stated that drug costs and patient OOP costs influence their 
treatment recommendations (92% and 94%, respectively). 
Moreover, most of the respondents believed that drug costs 
and patient OOP costs influence the ability of their patients 
to access treatments (96% and 98%, respectively). Seventy 
percent of oncologists strongly or somewhat agreed with 
the statement “I feel well-prepared to interpret and use 
cost‐effectiveness information in my treatment decisions,” 
Table 1. Demographic characteristics of the study sample
Mean Age (years) 46 (Range: 36-68) (%)
Gender
Male 88
Female 12
Practice setting
Public sector 46
Private sector 4
Public and private sector 50
Time passed from subspecialty oncology 
training graduation (years)
≤5 41
6-10 23
11-15 17
16-20 13
≥21 6
Average number of patient per week
≤50 17
51-100 42
101-150 14
≥151 27
and 74% of  oncologists strongly or somewhat agreed that 
“Every Iranian patient should have access to effective 
cancer treatments only if the treatments provide ‘good value 
for money’ or are cost‐effective.” Ninety-one percent of 
oncologists said that they always or frequently discuss cancer 
treatment costs with their patients.
Seventy-four percent of respondents believed that “over the 
next five years, costs of new cancer drugs will impose a need 
for governments to further restrict publicly funded access 
to some new and effective therapies” (Table 3). Eighty-four 
percent of respondents strongly or somewhat agreed with 
the statement “Government price controls for cancer drugs 
are needed,” and about 85% agreed that more use of cost‐
effectiveness data is required for decision-making about 
cancer drug coverage. Furthermore, 87% believed that more 
research on the comparative effectiveness of cancer drugs is 
needed. Just 7% agreed that more cost sharing for payment of 
cancer drugs is needed by patients. 
In response to the question “Who do you believe should 
determine whether a drug provides good value?,” all 
oncologists stated that academic groups (research centers and 
scientific societies) (81%) are the most eligible group for this 
position, followed by the MoH (43%), insurance companies 
(11%), and patients (11%) (more than one option could be 
selected).
Discussion
Our study results show that the high prices of new cancer 
drugs affect oncologists’ treatment recommendations and 
their patients’ access to effective treatments. More than 90% 
of oncologists stated that drug costs influence their treatment 
recommendations and the ability of their patients to access 
treatments. In a study conducted in the United States,3 56% 
of oncologists stated that the price of new cancer drugs 
affected their treatment recommendations and 84% of them 
stated that “Patient ‘OOP’ drug costs currently influence my 
decisions regarding which cancer treatments to recommend 
for my patients.” Also, in another study conducted in Canada, 
80% of oncologists agreed with this statement.22 
We found that Iranian oncologists discuss the costs of new 
cancer treatments with their patients (91%) more than those 
in the United States (43%),3 Canada (48%),22 and Israel 
(17%).26 This finding might be due to the fact that patients’ 
OOP payments in Iran were more than those in these 
countries. As mentioned before, OOP payments amount to 
over 50% of the total medical cost in Iran while the share 
of OOP payments of the total cancer medical cost in the 
United States was 8% during the 2001-2005 period.27 Using 
the WHO method and the threshold of 40% capacity to pay, 
and despite full health insurance coverage, about 68% of the 
households faced catastrophic health expenditures in a survey 
of 245 households with cancer patients in the Shiraz province 
of Iran in 2011. The risk of catastrophic health expenditures 
was significantly higher among patients who underwent 
chemotherapy.16 Berry et al,20 in their qualitative study in 
Canada, found that oncologists talk more with patients about 
access to drugs being limited due to funding decisions. The 
American Society of Clinical Oncology (ASCO) considers 
physician-patient communication about the cost of care 
to be an important component of high-quality care. ASCO 
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recommends that oncologists, in addition to direct medical 
costs, should consider direct nonmedical costs, such as travel 
costs and patient time cost, in relation to treatment options. 
Just recently, and in order to help oncologists involve patients 
in decision-making about clinical benefits and costs, ASCO 
designed and published a conceptual framework for assessing 
the value of new cancer treatment options based on clinical 
benefits, side effects and costs. The framework emphasizes 
the physician’s role as the patient’s trusted advocate, as well 
as their responsibility to be a good steward of healthcare 
resources who should facilitate patients’ access to both clinical 
and cost information about their treatment options.28
Previous studies have shown that despite cancer patients’ 
interest, usually only a few of them have the opportunity to 
discuss the cost of care with their physicians.8,29-32 In a survey 
on 45 Australian breast cancer patients conducted by Kaser et 
al,29 although 96% of patients wanted to discuss an expensive 
drug as an option with their oncologist, only 28% had discussed 
high-cost drugs treatment with their oncologist. In another 
survey on 134 breast cancer patients conducted by Irwin 
et al,32 most of the patients (94%) believed that physicians 
should discuss costs of care with patients, while only 14% of 
them discussed costs with their doctor. Likewise, the results of 
Bestvina et al33 study on 300 cancer patients showed that only 
Table 2. Attitude of the Iranian Oncologists (N = 52) Towards Cancer Drugs’ Costs and Cost-Effectiveness, 2014
Question
Percent Stating 
Strongly 
Agree
Somewhat 
Agree
Neither Agree 
or Disagree
Somewhat 
Disagree
Strongly 
Disagree
The costs of new cancer drugs currently influence my decisions regarding which 
cancer treatments to recommend for my patients
62 30 0 8 0
The costs of new cancer drugs currently influence my patients’ ability to access 
treatments.
63 33 0 4 0
Patient “out‐of‐pocket” drug costs currently influence my decisions regarding 
which cancer treatments to recommend for my patients.
56 38 2 4 0
Patient “out‐of‐pocket” drug costs currently influence my patients’ ability to 
access treatments.
63 35 2 0 0
I feel well‐prepared to interpret and use cost‐effectiveness information in my 
treatment decisions.
30 40 17 13 0
Every Iranian patient should have access to effective cancer treatments regardless 
of their cost.
21 39 20 16 4
Every Iranian patient should have access to effective cancer treatments only if the 
treatments provide “good value for money” or are cost‐effective.
46 28 13 11 2
Percent Frequency (N = 52)
How often do you discuss the costs of new cancer treatments with your patients?
Always 29
Frequently 62
Occasionally 6
Rarely 1
Never 2
Since we used the Berry et al22 study questionnaire in our study, therefore, the statements in the table are the same as those presented in their study.
Table 3. Attitude of the Iranian Oncologists (N = 52) Toward Cancer Drugs-Related Health Policies, 2014
Question
Percent Stating
Strongly 
Agree
Somewhat 
Agree
Neither Agree 
or Disagree
Somewhat 
Disagree
Strongly 
Disagree
Over the next 5 years, costs of new cancer drugs will impose a need for governments 
to further restrict publicly funded access to some new and effective therapies.
34 40 20 6 0
Government price controls for cancer drugs are needed. 59 25 8 6 2
More cost‐sharing by patients for payment of cancer drugs is needed. 3 4 10 60 23
More use of cost‐effectiveness data in funding decisions for cancer drugs is needed. 56 29 6 6 2
More research on the comparative effectiveness of cancer drugs is needed. 48 39 7 6 0
Percent Frequency (N = 52)
Who do you believe should determine whether a drug provides good value?a
Ministry of health 43
Insurance companies 11
Patients 11
Academic groups (research centers and scientific societies) 81
Other 6
Since we used the Berry et al22 study questionnaire in our study, therefore, the statements in the table are the same as those presented in their study. 
a Not mutually exclusive.
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19% of patients had talked about costs with their oncologist, 
while 27% had reported nonadherence to medication and 
22% did not fill a prescription because of the costs. Although, 
as is shown in some studies,24 most oncologists think that they 
are aware of their patients’ financial status, these data may 
refute such a perception of oncologists. Despite this, little is 
known about barriers to patient-oncologist communication 
in relation to the cost of care. Thus, it is important to identify 
the barriers and develop practical guidelines regarding cost 
communication. 
In Berry et al study,22 less than half of the oncologists in the 
United States and Canada feel well-prepared to use cost-
effectiveness information, whereas in our study a greater 
percentage of oncologists (70%) feel ready to use cost-
effectiveness information. In recent years, the increased 
cost of cancer treatment and high OOP payments in Iran 
have led oncologists to consider cost-effectiveness data in 
their treatment recommendations. In addition, the majority 
of oncologists in our study practice in the public sector and 
usually there is more emphasis on the cost-effectiveness of 
interventions in the this sector. 
The percentage of Iranian oncologists who believe that every 
patient should only have access to cost-effective drugs (74%) 
was similar to that among Canadian oncologists (75%) but 
was higher than among US oncologists (58%).22
In our study, the majority of oncologists believed that the 
government should have control over drug prices. In addition, 
most oncologists believed that more cost-effectiveness studies 
should be done and the results of these studies should be 
used in the decision-making process for drug funding. 
These findings indicate that Iranian oncologists are ready to 
help and support the government and health policy-makers 
in conducting economic evaluation studies and using the 
results of these studies in drug funding policy-making. Other 
countries’ experience has shown that health technology 
assessments and the use of their results in the allocation of 
resources can help make better use of available resources.9
Although the MoH and insurance companies currently 
determine whether a drug is cost-effective in Iran,17 the 
oncologists emphasized the importance of the role of academic 
groups, including university research centers and scientific 
societies, in making decisions about the cost-effectiveness 
of drugs. In Berry et al study,22 both the United States and 
Canadian oncologists believed that nonprofit agencies and 
physicians should determine whether a drug provides good 
value.
Oncologists have an important role in the decision-making 
process for drug reimbursement. They usually make decisions 
on behalf of  the patients and decide what treatment the 
patients should receive. In addition, clinical societies are 
too strong and may interfere with the decisions made by 
policy-makers.34 We found that although there are several 
shortcomings in the drug reimbursement system in Iran, 
Iranian oncologists are ready to help policy-makers overcome 
these limitations. This can be done through oncologists’ 
involvement in clinical research and the provision of required 
data about the costs and effectiveness of cancer drugs. 
Oncologists can also have crucial roles in the development of 
clinical practice guidelines. 
Clinical practice guidelines are one of the tools that can 
help to improve the quality of treatment and reduce its 
cost. Incorporating cost-effectiveness information into the 
guideline development process can reduce the cost of care.35 A 
small number of clinical guidelines have been developed and 
localized in Iran so far, and most of them face serious problems 
in their implementation. According to Baradaran-Seyed 
et al36 study, the “lack of an evidence-based stewardship 
for the healthcare system” and “the level of  knowledge, 
attitude and the abilities of the practitioner” were the most 
important barriers in the development and implementation 
of clinical guidelines in Iran. Oncologists and scientific 
societies, therefore, can play a major role in the removal of 
these barriers and the fostering of an evidence-based clinical 
practice in cancer care. 
To the best of our knowledge, this study is the first attempt to 
examine oncologists’ attitude toward the economic aspect of 
treatments in Iran. However, we faced some limitations. Only 
the oncologists who participated in the 13th Annual Congress 
of ISMOH were included in the study. However, although the 
sample size was small and may not be representative of all 
Iranian oncologists, most of the prominent and experienced 
oncologists participated in this congress and the results can 
be generalized to all Iranian oncologists. However, with 
the insights gathered from this study, it would be useful to 
conduct new studies in the future and apply other sampling 
methods to involve larger members of ISMOH. Furthermore, 
researchers have only analyzed the opinion of the oncologists 
on the impact of drug expenses on cancer care. It would also 
be informative to conduct parallel studies and compare the 
results from other stakeholders, in particular cancer patients 
and their caregivers. 
In conclusion, this study has shown that the high cost 
of new cancer drugs influences oncologists’ treatment 
recommendations and patients’ access to these cancer drugs 
in Iran. Oncologists need to put more time and effort into 
communication with their patients. Therefore, they are ready 
to support scientific evaluation of the economic burden of 
drugs in the country and participate in health technology 
assessments and the priority-setting process in order to 
optimize patients’ access to new expensive drugs. This 
situation creates a unique opportunity for the government to 
rely on scientific societies and find an appropriate solution for 
the improvement of patients’ access to high-quality care and 
essential chemotherapy drugs. 
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Appendix 1
Survey of Iranian medical oncologists’ attitude towards economic aspects, and policy-making in relation to new cancer drugs
Section I: Demographic Information (Please indicate or fill‐in your response)
1-	 Gender:   M   F
2-	 Age: ………year
3-	 Main practice setting:   
     Public sector       
     Private sector             
     Public and private sector 
4-	 Time passed from your subspecialty oncology training graduation: …………………year
5-	 Average number of patients you visit: ……………. patients per week
Section II: Attitudes
Please Indicate How Much You Agree or Disagree With the Following Statements: Strongly Agree
Somewhat 
Agree
Neither 
Agree or 
Disagree
Somewhat 
Disagree
Strongly 
Disagree
6 The costs of new cancer drugs currently influence my decisions regarding which 
cancer treatments to recommend for my patients
7
The costs of new cancer drugs currently influence my patients’ ability to access 
treatments.
8
Patient “out‐of‐pocket” drug costs currently influence my decisions regarding 
which cancer treatments to recommend for my patients.
9 Patient “out‐of‐pocket” drug costs currently influence my patients’ ability to 
access treatments.
10 I feel well‐prepared to interpret and use cost‐effectiveness information in my 
treatment decisions.
11 Every Iranian patient should have access to effective cancer treatments 
regardless of their cost.
12 Every Iranian patient should have access to effective cancer treatments only if 
the treatments provide “good value for money” or are cost‐effective.
13
Over the next 5 years, costs of new cancer drugs will impose a need for 
governments to further restrict publicly funded access to some new and effective 
therapies.
14 Government price controls for cancer drugs are needed.
15 More cost‐sharing by patients for payment of cancer drugs is needed.
16 More use of cost‐effectiveness data in funding decisions for cancer drugs is 
needed.
17 More research on the comparative effectiveness of cancer drugs is needed.
18‐ How often do you discuss the costs of cancer treatments with your patients? (Please check answer)
Always        Frequently            Occasionally              Rarely              Never
19‐ Who do you believe should determine whether a drug provides good value? (Please check all that apply)
Ministry of health                          
Patients                                     
Insurance companies                             
Academic groups (research centers and scientific societies)             
Other (please specify): ………………
